Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy

• Published in: Current treatment options in oncology 2020-01, Vol.21 (1), p.3-3, Article 3
• Main Authors: Sami, Shaheedul A., Darwish, Noureldien H. E., Barile, Amanda N. M., Mousa, Shaker A.
• Format: Article
• Language: English
• Subjects: Leukemia (PH Wiernik; Medicine; Medicine & Public Health; Oncology; Section Editor; Topical Collection on Leukemia
• ISSN: 1527-2729; 1534-6277
• DOI: 10.1007/s11864-019-0694-6

Opinion statement Acute myeloid leukemia (AML) disease prognosis is poor and there is a high risk of chemo-resistant relapse for both young and old patients. Thus, there is a demand for alternative and target-specific drugs to improve the 5-year survival rate. Current treatment mainstays include chemotherapy, or mutation-specific targeting molecules including FLT3 inhibitors, IDH inhibitors, and monoclonal antibodies. Efforts to devise new, targeted therapy have included recent advances in methods for high-throughput genomic screening and the availability of computer-assisted techniques for the design of novel agents predicted to specifically inhibit mutant molecules involved in leukemogenesis. Crosstalk between the leukemia cells and the bone marrow microenvironment through cell surface molecules, such as the integrins αvβ3 and αvβ5, might influence drug response and AML progression. This review article focuses on current AML treatment options, new AML targeted therapies, the role of integrins in AML progression, and a potential therapeutic agent—integrin αvβ3 antagonist.